Novel off-target effect of tamoxifen - Inhibition of acid ceramidase activity in cancer cells

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 12, 2013, Pages 1657-1664

  Morad, Samy A F ^a,b   Levin, Jonathan C ^a   Tan, Su Fern ^b   Fox, Todd E ^b   Feith, David J ^b   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Acid ceramidase; Antiestrogen; Ceramide; Lysosomal protease; Tamoxifen

Indexed keywords

AC PROTEIN; ACID CERAMIDASE; CATHEPSIN B INHIBITOR; MEMBRANE PROTEIN; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL FREE SYSTEM; CELL MIGRATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LYSOSOME MEMBRANE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AC; ACID CERAMIDASE; ACRIDINE ORANGE; ANTIESTROGEN; AO; CERAMIDE; GC; GLUCOSYLCERAMIDE; LMP; LYSOSOMAL MEMBRANE PERMEABILITY; LYSOSOMAL PROTEASE; N-OLEOYLETHANOLAMINE; NOE; PBS; PBST; PHENYLMETHYLSULFONYL FLUORIDE; PHOSPHATE-BUFFERED SALINE; PHOSPHATE-BUFFERED SALINE WITH TWEEN-20; PMSF; S1-P; SK; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE; TAMOXIFEN;

ACID CERAMIDASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATHEPSIN B; CELL LINE, TUMOR; CELL SURVIVAL; CELL-FREE SYSTEM; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HUMANS; HYDROGEN-ION CONCENTRATION; LYSOPHOSPHOLIPIDS; LYSOSOMES; MALE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPHINGOSINE; TAMOXIFEN; TOREMIFENE;

SPHINGOIDEA;

EID: 84884742514     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2013.07.016     Document Type: Article

References (54)

1. S. Gatt Enzymic hydrolysis and synthesis of ceramides J. Biol. Chem. 238 1963 3131 3133
2. S.A. Morad, and M.C. Cabot Ceramide-orchestrated signalling in cancer cells Nat. Rev. Cancer 13 2013 51 65
3. D. Shida, K. Takabe, D. Kapitonov, S. Milstien, and S. Spiegel Targeting SphK1 as a new strategy against cancer Curr. Drug Targets 9 2008 662 673
4. J.R. Brocklyn Regulation of cancer cell migration and invasion by sphingosine-1-phosphate World J. Biol. Chem. 1 2010 307 312
5. X. He, N. Okino, R. Dhami, A. Dagan, S. Gatt, H. Schulze, K. Sandhoff, and E.H. Schuchman Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase J. Biol. Chem. 278 2003 32978 32986 (Pubitemid 37055742)
6. J.H. Park, and E.H. Schuchman Acid ceramidase and human disease Biochim. Biophys. Acta 1758 2006 2133 2138 (Pubitemid 44879370)
7. A. Nilsson The presence of spingomyelin- and ceramide-cleaving enzymes in the small intestinal tract Biochim. Biophys. Acta 176 1969 339 347
8. W. Hu, R. Xu, W. Sun, Z.M. Szulc, J. Bielawski, L.M. Obeid, and C. Mao Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosis J. Biol. Chem. 285 2010 7964 7976
9. X. Liu, S. Elojeimy, L.S. Turner, A.E. Mahdy, Y.H. Zeidan, A. Bielawska, J. Bielawski, J.Y. Dong, A.M. El-Zawahry, G.W. Guo, Y.A. Hannun, D.H. Holman, S. Rubinchik, Z. Szulc, T.E. Keane, M. Tavassoli, and J.S. Norris Acid ceramidase inhibition: a novel target for cancer therapy Front. Biosci. 13 2008 2293 2298 (Pubitemid 351589254)
10. T.H. Beckham, P. Lu, J.C. Cheng, D. Zhao, L.S. Turner, X. Zhang, S. Hoffman, K.E. Armeson, A. Liu, T. Marrison, Y.A. Hannun, and X. Liu Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B Int. J. Cancer 131 2012 2034 2043
11. A.E. Mahdy, J.C. Cheng, J. Li, S. Elojeimy, W.D. Meacham, L.S. Turner, A. Bai, C.R. Gault, A.S. McPherson, N. Garcia, T.H. Beckham, A. Saad, A. Bielawska, J. Bielawski, Y.A. Hannun, T.E. Keane, M.I. Taha, H.M. Hammouda, J.S. Norris, and X. Liu Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer Mol. Ther. 17 2009 430 438
12. R.S. Seelan, C. Qian, A. Yokomizo, D.G. Bostwick, D.I. Smith, and W. Liu Human acid ceramidase is overexpressed but not mutated in prostate cancer Genes Chromosomes Cancer 29 2000 137 146
13. S.A. Morad, M.C. Messner, J.C. Levin, N. Abdelmageed, H. Park, A.H. Merrill Jr., and M.C. Cabot Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells Cancer Chemother. Pharmacol. 71 2013 635 645
14. C. Bedia, J. Casas, N. Andrieu-Abadie, G. Fabrias, and T. Levade Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine J. Biol. Chem. 286 2011 28200 28209
15. G. Musumarra, V. Barresi, D.F. Condorelli, and S. Scire A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics Biol. Chem. 384 2003 321 327 (Pubitemid 36348334)
16. D. Canals, D.M. Perry, R.W. Jenkins, and Y.A. Hannun Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases Br. J. Pharmacol. 163 2011 694 712
17. C. Bedia, D. Canals, X. Matabosch, Y. Harrak, J. Casas, A. Llebaria, A. Delgado, and G. Fabrias Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides Chem. Phys. Lipids 156 2008 33 40
18. D.H. Holman, L.S. Turner, A. El-Zawahry, S. Elojeimy, X. Liu, J. Bielawski, Z.M. Szulc, K. Norris, Y.H. Zeidan, Y.A. Hannun, A. Bielawska, and J.S. Norris Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells Cancer Chemother. Pharmacol. 61 2008 231 242 (Pubitemid 350160321)
19. V. Gouaze-Andersson, M. Flowers, R. Karimi, G. Fabrias, A. Delgado, J. Casas, and M.C. Cabot Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide Prostate 71 2011 1064 1073
20. M. Flowers, G. Fabrias, A. Delgado, J. Casas, J.L. Abad, and M.C. Cabot C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth Breast Cancer Res. Treat. 133 2012 447 458
21. M. Selzner, A. Bielawska, M.A. Morse, H.A. Rudiger, D. Sindram, Y.A. Hannun, and P.A. Clavien Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer Cancer Res. 61 2001 1233 1240 (Pubitemid 32174448)
22. A. Senchenkov, D.A. Litvak, and M.C. Cabot Targeting ceramide metabolism - a strategy for overcoming drug resistance J. Natl. Cancer Inst. 93 2001 347 357 (Pubitemid 32229379)
23. A. Delgado, G. Fabrias, C. Bedia, J. Casas, and J.L. Abad Sphingolipid modulation: a strategy for cancer therapy Anticancer Agents Med Chem. 12 2012 285 302
24. S. Mandlekar, and A.N. Kong Mechanisms of tamoxifen-induced apoptosis Apoptosis 6 2001 469 477 (Pubitemid 33078758)
25. P. de Medina, G. Favre, and M. Poirot Multiple targeting by the antitumor drug tamoxifen: a structure-activity study Curr. Med. Chem. Anticancer Agents 4 2004 491 508 (Pubitemid 39406262)
26. S.A. Morad, J.C. Levin, S.S. Shanmugavelandy, M. Kester, G. Fabrias, C. Bedia, and M.C. Cabot Ceramide - antiestrogen nanoliposomal combinations - novel impact of hormonal therapy in hormone-insensitive breast cancer Mol. Cancer Ther. 11 2012 2352 2361
27. Y. Lavie, H. Cao, A. Volner, A. Lucci, T.Y. Han, V. Geffen, A.E. Giuliano, and M.C. Cabot Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells J. Biol. Chem. 272 1997 1682 1687 (Pubitemid 27043253)
28. C. Bedia, J. Casas, V. Garcia, T. Levade, and G. Fabrias Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases Chembiochem 8 2007 642 648 (Pubitemid 47194856)
29. T. Kirkegaard, A.G. Roth, N.H. Petersen, A.K. Mahalka, O.D. Olsen, I. Moilanen, A. Zylicz, J. Knudsen, K. Sandhoff, C. Arenz, P.K. Kinnunen, J. Nylandsted, and M. Jaattela Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology Nature 463 2010 549 553
30. E.G. Bligh, and W.J. Dyer A rapid method of total lipid extraction and purification Can. J. Biochem. Physiol. 37 1959 911 917
31. T.E. Fox, M.C. Bewley, K.A. Unrath, M.M. Pedersen, R.E. Anderson, D.Y. Jung, L.S. Jefferson, J.K. Kim, S.K. Bronson, J.M. Flanagan, and M. Kester Circulating sphingolipid biomarkers in models of type 1 diabetes J. Lipid Res. 52 2011 509 517
32. M.C. Cabot, A.E. Giuliano, A. Volner, and T.Y. Han Tamoxifen retards glycosphingolipid metabolism in human cancer cells FEBS Lett. 394 1996 129 131 (Pubitemid 26341491)
33. R. Verger Interfacial enzyme kinetics of lipolysis Annu. Rev. Biophys. Bioeng. 5 1976 77 117
34. A.F. Saad, W.D. Meacham, A. Bai, V. Anelli, S. Elojeimy, A.E. Mahdy, L.S. Turner, J. Cheng, A. Bielawska, J. Bielawski, T.E. Keane, L.M. Obeid, Y.A. Hannun, J.S. Norris, and X. Liu The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy Cancer Biol. Ther. 6 2007 1455 1460 (Pubitemid 351590358)
35. N.C. Lucki, and M.B. Sewer Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression J. Biol. Chem. 286 2011 19399 19409
36. Y. Akao, Y. Banno, Y. Nakagawa, N. Hasegawa, T.J. Kim, T. Murate, Y. Igarashi, and Y. Nozawa High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation Biochem. Biophys. Res. Commun. 342 2006 1284 1290
37. A. Dayon, L. Brizuela, C. Martin, C. Mazerolles, N. Pirot, N. Doumerc, L. Nogueira, M. Golzio, J. Teissie, G. Serre, P. Rischmann, B. Malavaud, and O. Cuvillier Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival PLoS One 4 2009 e8048
38. H. Matsuoka, M. Tsubaki, Y. Yamazoe, M. Ogaki, T. Satou, T. Itoh, T. Kusunoki, and S. Nishida Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways Exp. Cell Res. 315 2009 2022 2032
39. S.A. Morad, J.P. Madigan, J.C. Levin, N. Abdelmageed, R. Karimi, D.W. Rosenberg, M. Kester, S.S. Shanmugavelandy, and M.C. Cabot Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53 Biochem. Pharmacol. 85 2013 1057 1065
40. L.Z. Shen, Y.B. Hua, X.M. Yu, Q. Xu, T. Chen, J.H. Wang, and W.X. Wu Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo World J. Gastroenterol. 11 2005 1060 1064 (Pubitemid 40347765)
41. Y. Nakayama, H. Sakamoto, K. Satoh, and T. Yamamoto Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system Cancer Lett. 161 2000 63 71
42. D.J. Lindner, and E.C. Borden Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro J. Interferon Cytokine Res. 17 1997 681 693 (Pubitemid 27518010)
43. P. Lointier, D.M. Wildrick, and B.M. Boman Growth effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa Anticancer Res. 12 1992 1523 1525
44. P. de Medina, B.L. Payre, J. Bernad, I. Bosser, B. Pipy, S. Silvente-Poirot, G. Favre, J.C. Faye, and M. Poirot Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells J. Pharmacol. Exp. Ther. 308 2004 1165 1173 (Pubitemid 38263994)
45. J. Rosell, B. Nordenskjold, N.O. Bengtsson, T. Fornander, T. Hatschek, H. Lindman, P.O. Malmstrom, A. Wallgren, O. Stal, and J. Carstensen Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up Breast Cancer Res. Treat. 138 2013 467 473
46. O.M. Dorchies, J. Reutenauer-Patte, E. Dahmane, H.M. Ismail, O. Petermann, O. Patthey-Vuadens, S.A. Comyn, E. Gayi, T. Piacenza, R.J. Handa, L.A. Decosterd, and U.T. Ruegg The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy Am. J. Pathol. 182 2013 485 504
47. B.M. Barth, S.S. Shanmugavelandy, D.M. Tacelosky, M. Kester, S.A. Morad, and M.C. Cabot Gaucher's disease and cancer: a sphingolipid perspective Crit. Rev. Oncog. 18 2013 221 234
48. S.D. Larsen, M.W. Wilson, A. Abe, L. Shu, C.H. George, P. Kirchhoff, H.D. Showalter, J. Xiang, R.F. Keep, and J.A. Shayman Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain J. Lipid Res. 53 2012 282 291
49. J.V. Chapman, V. Gouaze-Andersson, and M.C. Cabot Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity Int. J. Oncol. 37 2010 1591 1597
50. S.S. Taneja, M.R. Smith, J.T. Dalton, S. Raghow, G. Barnette, M. Steiner, and K.A. Veverka Toremifene - a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy Expert Opin. Investig. Drugs 15 2006 293 305 (Pubitemid 43338149)
51. D. Price, B. Stein, P. Sieber, R. Tutrone, J. Bailen, E. Goluboff, D. Burzon, D. Bostwick, and M. Steiner Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial J. Urol. 176 2006 965 970 (discussion 970-961)
52. S. Raghow, M.Z. Hooshdaran, S. Katiyar, and M.S. Steiner Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model Cancer Res. 62 2002 1370 1376 (Pubitemid 34407794)
53. M. Sawaki, M. Wada, Y. Sato, Y. Mizuno, H. Kobayashi, K. Yokoi, M. Yoshihara, K. Kamei, M. Ohno, and T. Imai High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: a multicenter phase II study Oncol. Lett. 3 2012 61 65
54. P.N. Lara Jr., D.R. Gandara, J. Longmate, P.H. Gumerlock, D.H. Lau, M.J. Edelman, R. Gandour-Edwards, P.C. Mack, V. Israel, J. Raschko, P. Frankel, E.A. Perez, H.J. Lenz, and J.H. Doroshow Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial Cancer Chemother. Pharmacol. 48 2001 22 28 (Pubitemid 32662432)